Latest Glycemia Stories
High blood glucose levels after surgery may be an important risk factor for infection at the surgical site in patients having general surgery.
STOCKHOLM, September 20, 2010 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY)(http://www.bms.com) and AstraZeneca (NYSE: AZN)(http://www.astrazeneca-us.com) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes...
Research finds Type 1 diabetes affects athletic performance, but can be managed.
PARIS, June 25 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included LantusÂ® (insulin glargine [rDNA origin] injection) once-daily and ApidraÂ® (insulin glulisine [rDNA origin] injection) before meals improved glycemic...
WINSTON-SALEM, N.C., June 8 /PRNewswire/ -- The "gold standard" diabetes test, Hemoglobin A1c (A1C), explains much less about the risk of cardiovascular complications in patients with diabetes than originally thought, according to an article in the June 9 issue of the Journal of the American Medical Association (JAMA).
Previous studies have shown that GI is a reproducible measure of day-long postprandial glycemia.
SUNNYVALE, Calif., Jan. 5 /PRNewswire/ -- Intuity Medical, Inc., a privately-held company developing innovative technologies in diabetes management, today announced that it has secured a $64M Series D financing round.
Routine self-monitoring of blood glucose levels by people with type 2 diabetes who are not taking insulin is an ineffective use of health resources as the modest benefits are outweighed by the significant cost of test strips, suggest 2 studies http://www.cmaj.ca/embargo/cmaj091017.pdf and http://www.cmaj.ca/embargo/cmaj090765.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.
NEW YORK, Dec.
EDINA, Minn., Nov. 12 /PRNewswire/ -- ARKRAY, Inc., the world's 5th largest manufacturer of diabetes self-monitoring systems, today announced the launch of a new and improved Assure Pro Blood Glucose Monitoring Test Strip.
- A political dynamiter.